Eiger BioPharmaceuticals Stock Price, News & Analysis (NASDAQ:EIGR) $0.32 +0.00 (+0.13%) (As of 03:02 PM ET) Add Compare Share Share Today's Range$0.31▼$0.3450-Day Range$0.22▼$0.4352-Week Range$0.21▼$2.98Volume130,111 shsAverage Volume450,057 shsMarket Capitalization$14.20 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Eiger BioPharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,670.8% Upside$5.67 Price TargetShort InterestHealthy2.28% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment0.34Based on 3 Articles This WeekInsider TradingAcquiring Shares$44,181 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.64) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.74 out of 5 starsMedical Sector58th out of 958 stocksBiological Products, Except Diagnostic Industry6th out of 143 stocks 3.5 Analyst's Opinion Consensus RatingEiger BioPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.67, Eiger BioPharmaceuticals has a forecasted upside of 1,670.8% from its current price of $0.32.Amount of Analyst CoverageEiger BioPharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.28% of the outstanding shares of Eiger BioPharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEiger BioPharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eiger BioPharmaceuticals has recently decreased by 5.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEiger BioPharmaceuticals does not currently pay a dividend.Dividend GrowthEiger BioPharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEiger BioPharmaceuticals has received a 61.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Lonafarnib" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Eiger BioPharmaceuticals is -1.65. Previous Next 1.9 News and Social Media Coverage News SentimentEiger BioPharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eiger BioPharmaceuticals this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Eiger BioPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eiger BioPharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $44,181.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.54% of the stock of Eiger BioPharmaceuticals is held by insiders.Percentage Held by Institutions62.46% of the stock of Eiger BioPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Eiger BioPharmaceuticals are expected to grow in the coming year, from ($1.64) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eiger BioPharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eiger BioPharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEiger BioPharmaceuticals has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.Read More EIGR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EIGR Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comEiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Sees Large Decrease in Short InterestDecember 4, 2023 | finance.yahoo.comEiger BioPharmaceuticals Insiders US$2.1m Short Of Breakeven On Stock PurchaseDecember 7, 2023 | Edge On The Street (Ad)Henry Ford Would NEVER Have Seen This ComingIn 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.December 3, 2023 | americanbankingnews.comEiger BioPharmaceuticals (NASDAQ:EIGR) Coverage Initiated by Analysts at StockNews.comNovember 11, 2023 | finanznachrichten.deEiger BioPharmaceuticals, Inc.: Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateSeptember 15, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Ocular Therapeutix (OCUL), Eiger Biopharmaceuticals (EIGR)September 13, 2023 | marketwatch.comEiger BioPharmaceuticals Shares Hit New Lows After Scrapped Hepatitis D StudySeptember 13, 2023 | markets.businessinsider.comEiger To Discontinue Peginterferon Lambda Trial In CHD Patients; Stock Down In PremarketDecember 7, 2023 | Edge On The Street (Ad)The Battery Metal Nobody Told You AboutAccording to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech." September 13, 2023 | msn.comWhy Is Hepatitis Player Eiger BioPharma Stock Trading Lower Today?September 13, 2023 | investorplace.comWhy Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?September 13, 2023 | reuters.comEiger to discontinue late-stage hepatitis drug study over safety concernsSeptember 12, 2023 | news.yahoo.comEiger to discontinue hepatitis drug study over safety concernsSeptember 12, 2023 | marketwatch.comEiger BioPharmaceuticals to Discontinue Chronic Hepatitis Delta Study, Ends Licensing TalksSeptember 12, 2023 | seekingalpha.comEiger to stop late stage trial in hepatitis D patients, stock slumps ~36% after hoursSeptember 12, 2023 | finance.yahoo.comUPDATE 1-Eiger to discontinue hepatitis drug study over safety concernsSeptember 12, 2023 | reuters.comEiger to discontinue hepatitis drug studyAugust 30, 2023 | markets.businessinsider.comCiti Sticks to Their Buy Rating for Eiger Biopharmaceuticals (EIGR)August 15, 2023 | finanznachrichten.deEiger BioPharmaceuticals, Inc.: Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Eiger Biopharmaceuticals (EIGR) and Atossa Therapeutics (ATOS)August 14, 2023 | markets.businessinsider.comEiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 3, 2023 | yahoo.comFreewell Eiger matte box aims to transform your filmmakingJuly 6, 2023 | msn.comEiger BioPharmaceuticals (EIGR) Price Target Decreased by 59.60% to 3.40July 1, 2023 | msn.comBaird Maintains Eiger BioPharmaceuticals (EIGR) Outperform RecommendationJune 30, 2023 | markets.businessinsider.comPotential Upside For Eiger's Avexitide In Both PBH And CHI Indications: AnalystJune 29, 2023 | msn.comEiger cuts 25% of staff in portfolio reorganizationJune 29, 2023 | msn.comEiger BioPharmaceuticals Makes Interim CEO Permanent, It Chalks Out Portfolio Prioritization Review, LayoffsSee More Headlines Receive EIGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EIGR CUSIPN/A CIK1305253 Webwww.eigerbio.com Phone(650) 272-6138Fax650-618-1621Employees56Year FoundedN/APrice Target and Rating Average Stock Price Target$5.67 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,670.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,780,000.00 Net Margins-590.80% Pretax Margin-590.79% Return on Equity-332.49% Return on Assets-99.77% Debt Debt-to-Equity Ratio2.64 Current Ratio3.31 Quick Ratio3.24 Sales & Book Value Annual Sales$13.48 million Price / Sales1.05 Cash FlowN/A Price / Cash FlowN/A Book Value$1.25 per share Price / Book0.26Miscellaneous Outstanding Shares44,380,000Free Float42,814,000Market Cap$14.20 million OptionableNot Optionable Beta1.98 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. David Apelian M.B.A. (Age 58)M.D., Ph.D., CEO & Director Comp: $204.39kDr. Jeffrey S. Glenn M.D. (Age 60)Ph.D., Scientific Founder & Independent Director Comp: $67kMr. Eldon C. Mayer III (Age 62)M.B.A., Chief Commercial Officer Comp: $586.96kMr. William G. Kaichoff CPA (Age 57)CFO and Principal Financial & Accounting Officer Mr. Christopher A. Kurtz (Age 56)Chief Technical Officer Mr. James Vollins J.D. (Age 54)General Counsel, Chief Compliance Officer & Corporate Secretary Dr. Ingrid C. ChoongSenior Vice President of Clinical DevelopmentDr. Colin Hislop M.D. (Age 65)MBBS, Senior Vice President of Clinical & Development Operations More ExecutivesKey CompetitorsBrainstorm Cell TherapeuticsNASDAQ:BCLIProtara TherapeuticsNASDAQ:TARAAcorda TherapeuticsNASDAQ:ACORPHAXIAM TherapeuticsNASDAQ:PHXMEvaxion Biotech A/SNASDAQ:EVAXView All CompetitorsInsiders & InstitutionsGSA Capital Partners LLPBought 70,190 shares on 11/15/2023Ownership: 0.802%683 Capital Management LLCSold 1,100,000 shares on 11/14/2023Ownership: 5.982%Richard A KayneBought 23,398 shares on 11/2/2023Total: $7,019.40 ($0.30/share)Richard A KayneBought 154,841 shares on 10/31/2023Total: $37,161.84 ($0.24/share)Eldon C Mayer IIISold 4,395 sharesTotal: $4,702.65 ($1.07/share)View All Insider TransactionsView All Institutional Transactions EIGR Stock Analysis - Frequently Asked Questions Should I buy or sell Eiger BioPharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EIGR shares. View EIGR analyst ratings or view top-rated stocks. What is Eiger BioPharmaceuticals' stock price target for 2024? 2 Wall Street research analysts have issued 1 year price objectives for Eiger BioPharmaceuticals' shares. Their EIGR share price targets range from $3.00 to $9.00. On average, they predict the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 1,670.8% from the stock's current price. View analysts price targets for EIGR or view top-rated stocks among Wall Street analysts. How have EIGR shares performed in 2023? Eiger BioPharmaceuticals' stock was trading at $1.18 at the start of the year. Since then, EIGR shares have decreased by 72.9% and is now trading at $0.32. View the best growth stocks for 2023 here. Are investors shorting Eiger BioPharmaceuticals? Eiger BioPharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 1,010,000 shares, a decrease of 5.6% from the October 31st total of 1,070,000 shares. Based on an average daily trading volume, of 324,600 shares, the days-to-cover ratio is presently 3.1 days. View Eiger BioPharmaceuticals' Short Interest. When is Eiger BioPharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our EIGR earnings forecast. How were Eiger BioPharmaceuticals' earnings last quarter? Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.41) earnings per share for the quarter. The biotechnology company earned $3.21 million during the quarter. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%. What ETF holds Eiger BioPharmaceuticals' stock ? Simplify Propel Opportunities ETF holds 1,099,653 shares of EIGR stock, representing 0.75% of its portfolio. What other stocks do shareholders of Eiger BioPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO). Who are Eiger BioPharmaceuticals' major shareholders? Eiger BioPharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include 683 Capital Management LLC (5.98%), GSA Capital Partners LLP (0.80%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Evan Loh, Richard A Kayne, Sriram Ryali and Thomas John Dietz. View institutional ownership trends. How do I buy shares of Eiger BioPharmaceuticals? Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:EIGR) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eiger BioPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.